Urine flow rate-guided hydration, as opposed to left ventricular end-diastolic pressure-guided hydration, could prevent more complications in CKD patients who are at a high risk for contrast-induced kidney injury.

The American College of Radiology released the contrast-specific LI-RADS system in response to the widespread use of the material in clinical practice. To date, however, few studies have analyzed its interreader agreement, and in those that have, results have been inconsistent.

Using contrast-enhanced digital mammography (CEDM) to evaluate low to moderately suspicious breast lesions can greatly reduce biopsies in patients with benign lesions, according to a study published Sept. 5 in Academic Radiology.

Patients with a family or personal history of allergic reactions to contrast media are in danger of experiencing future reactions, according to a study published Sept. 3 in Radiology.  

The new agent is manganese-based (Mn-PyC3A) and produces tumor contrast enhancement similarly to that seen when using “state of the art” gadolinium-based contrast agents (GBCAs).

A skin test may help clinicians prevent adverse drug reactions in patients receiving radiocontrast material, according to a new study published in the American Journal of Roentgenology.

A new study found that chronic kidney disease patients who received IV contrast-enhanced imaging faced no more risk of developing contrast-induced nephropathy than those who did not receive contrast material.

The FDA has approved Bayer’s gadobutrol (Gadavist) injection for use in cardiac MRI, making it the first contrast agent approved for the imaging technique, according to a statement from Bayer.